Edwards Lifesciences (NYSE:EW) Share Price Breaks Above Two Hundred Day Moving Average - What's Next?

Key Points

• Edwards Lifesciences shares rose above their 200-day moving average of $86.11, trading as high as $87.57 and most recently around $87.29.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating from 23 analysts and an average price target of $100.27; several firms recently raised targets or upgraded the stock.
• The company recently exceeded quarterly expectations, reporting adjusted EPS of $0.78 versus $0.74 expected and revenue of $1.74 billion, up 13.6% year over year. Insiders have sold shares in recent months, while institutional investors own approximately 79.5% of the stock.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $86.11 and traded as high as $87.57. Edwards Lifesciences shares last traded at $87.2850, with a volume of 3,315,836 shares.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Mizuho boosted their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a report on Wednesday, July 15th. Leerink Partners upgraded shares of Edwards Lifesciences from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. BTIG Research reiterated a "buy" rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 11th. Finally, Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, September 26th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

The company has a market capitalization of $50.26 billion, a PE ratio of 50.16, a price-to-earnings-growth ratio of 2.23 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The stock's 50 day simple moving average is $88.74 and its 200-day simple moving average is $86.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same period last year, the firm earned $0.67 earnings per share. The company's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company's stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,045 shares of company stock worth $455,341 in the last 90 days. Corporate insiders own 0.31% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in EW. Pin Oak Investment Advisors Inc. purchased a new stake in Edwards Lifesciences during the second quarter worth approximately $26,000. TrinityBridge Ltd acquired a new stake in Edwards Lifesciences during the second quarter worth approximately $27,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $28,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.